Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | BRD2 | P25440 | 2/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16984175 | 0.94 | SLC9A1 (0.34) | SLC9A1KEAP1DRD4TOP2ABRD4 | |
| SCHEMBL20693320 | 0.86 | SLC9A1 (0.38) | SLC9A1DRD4TOP2ATP53SMN1; SMN2 | |
| SCHEMBL24180939 | 0.86 | DRD4 (0.35) | SLC9A1KEAP1DRD4TOP2ABRD4 | |
| SCHEMBL24506189 | 0.86 | DRD4 (0.33) | DRD4BRD4BRD2BRD3KDM4E | |
| SCHEMBL19049876 | 0.86 | DRD4 (0.35) | SLC9A1KEAP1DRD4TOP2ABRD4 | |
| SCHEMBL24140358 | 0.86 | BRD2 (0.34) | SLC9A1KEAP1DRD4TOP2ABRD4 | |
| SCHEMBL25777198 | 0.85 | SLC9A1 (0.41) | SLC9A1TOP2AADRA2AKMT2AIDO1 | |
| SCHEMBL19199065 | 0.85 | TOP2A (0.37) | DRD4TOP2ABRD4BRD2BRD3 | |
| SCHEMBL24440155 | 0.83 | TSHR (0.33) | DRD4BRD4BRD2BRD3KDM4E | |
| SCHEMBL21117274 | 0.83 | DRD4 (0.31) | SLC9A1KEAP1DRD4TOP2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064771-A1 | ANTI-CD45-IGN ANTIBODY DRUG CONJUGATES AND USES THEREOF | VOR BIOPHARMA INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023196224-A1 | BIVALIRUDIN COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230248842-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | AbTis Co., Ltd. (KR) | 2023-08-10 | — | — | US | disclosed |
| WO-2023141474-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023137026-A1 | CAMPTOTHECIN ANALOGS CONJUGATED TO A GLUTAMINE RESIDUE IN A PROTEIN, AND THEIR USE | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023124537-A1 | CONJUGATE AND ANTIBODY-DRUG CONJUGATE PREPARED USING SAME | 辽宁键凯科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20170360954-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | CRISPR THERAPEUTICS AG (CH) | 2017-12-21 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170119851-A1 | METHODS OF TREATING ANOREXIA | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160362439-A1 | CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-15 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160264626-A1 | METHOD FOR PRODUCING PEPTIDE HYDRAZIDE, PEPTIDE AMIDE, AND PEPTIDE THIOESTER | AJINOMOTO CO., INC. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20150218220-A1 | AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | AGENSYS, INC. | 2015-08-06 | — | — | US | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | SLC9A1 3393/4885KEAP1 1639/4885DRD4 4703/4885 |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | SLC9A1 4316/4885KEAP1 713/4885DRD4 4743/4885 |
| US-20170360954-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | CD2, CD47, SIGLEC7 | SLC9A1 1237/4885KEAP1 4228/4885DRD4 3653/4885 |
| US-20160264626-A1 | METHOD FOR PRODUCING PEPTIDE HYDRAZIDE, PEPTIDE AMIDE, AND PEPTIDE THIOESTER | VIP, PPT1, NPPA | SLC9A1 2813/4885KEAP1 628/4885DRD4 3789/4885 |
| US-20170119851-A1 | METHODS OF TREATING ANOREXIA | CRH, VIP, GIPR | SLC9A1 3850/4885KEAP1 3577/4885DRD4 3904/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | SLC9A1 988/4885KEAP1 797/4885DRD4 987/4885 |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | SLC9A1 3408/4885KEAP1 856/4885DRD4 2512/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | SLC9A1 3849/4885KEAP1 3603/4885DRD4 4799/4885 |
| US-20160362439-A1 | CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS | GPX4, PRDX1, PRDX3 | SLC9A1 310/4885KEAP1 1097/4885DRD4 2229/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | SLC9A1 3290/4885KEAP1 1522/4885DRD4 3447/4885 |
| US-20150218220-A1 | AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | SLC9A1 3556/4885KEAP1 3687/4885DRD4 2141/4885 |
| US-20230248842-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | EEA1, CD47, FCGR2A | SLC9A1 4027/4885KEAP1 1628/4885DRD4 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.